Dana Farber Cancer Institute — Boston, Massachusetts

Public research footprint of Dana Farber Cancer Institute, compiled from the ClinicalTrials.gov public registry.

3,900

Registered studies

1,278

Active

622

Recruiting now

1,954

Completed

554

Stopped or withdrawn

Most-studied conditions

Myelodysplastic Syndrome · Locally Advanced Malignant Solid Neoplasm · Metastatic Non-Cutaneous Melanoma · Recurrent Non-Cutaneous Melanoma

Recently updated registry entries

NCT03775265 — Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle… (Active Not Recruiting)
NCT03712605 — Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After… (Active Not Recruiting)
NCT05675410 — A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs… (Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Dana Farber Cancer Institute?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 02, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.